HRAS Codon 12 Missense
Associated Genetic Biomarkers
HRAS Codon 12 Missense is present in 0.12% of AACR GENIE cases, with bladder urothelial carcinoma, oral cavity squamous cell carcinoma, infiltrating renal pelvis and ureter urothelial carcinoma, head and neck squamous cell carcinoma, and breast invasive ductal carcinoma having the greatest prevalence .
HRAS Codon 12 Missense serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains HRAS Codon 12 Missense as an inclusion criterion, 1 is phase 2 (1 open).
Trials with HRAS Codon 12 Missense in the inclusion eligibility criteria most commonly target thyroid gland carcinoma .
Trametinib is the most frequent therapy in trials with HRAS Codon 12 Missense as an inclusion criteria .
Significance of HRAS Codon 12 Missense in Diseases
Thyroid Gland Carcinoma +
HRAS is altered in 5.05% of thyroid gland carcinoma patients .
HRAS Codon 12 Missense is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS Codon 12 Missense and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.